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Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease
characterized by recurrent episodes of mania and depression. Lithium is the
best-established long-term treatment for BD, even though individual response is highly
variable. Evidence suggests that some of this variability has a genetic basis. This is
supported by the largest genome-wide association study (GWAS) of lithium response
to date conducted by the International Consortium on Lithium Genetics (ConLiGen).
Recently, we performed the first genome-wide analysis of the involvement of miRNAs
in BD and identified nine BD-associated miRNAs. However, it is unknown whether these
miRNAs are also associated with lithium response in BD. In the present study, we
therefore tested whether common variants at these nine candidate miRNAs contribute to
the variance in lithium response in BD. Furthermore, we systematically analyzed whether
any other miRNA in the genome is implicated in the response to lithium. For this purpose,
we performed gene-based tests for all known miRNA coding genes in the ConLiGen
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GWAS dataset (n = 2,563 patients) using a set-based testing approach adapted from
the versatile gene-based test for GWAS (VEGAS2). In the candidate approach, miR-
499a showed a nominally significant association with lithium response, providing some
evidence for involvement in both development and treatment of BD. In the genome-
wide miRNA analysis, 71 miRNAs showed nominally significant associations with the
dichotomous phenotype and 106 with the continuous trait for treatment response. A total
of 15 miRNAs revealed nominal significance in both phenotypes with miR-633 showing
the strongest association with the continuous trait (p = 9.80E-04) and miR-607 with the
dichotomous phenotype (p= 5.79E-04). No association betweenmiRNAs and treatment
response to lithium in BD in either of the tested conditions withstood multiple testing
correction. Given the limited power of our study, the investigation of miRNAs in larger
GWAS samples of BD and lithium response is warranted.
Keywords: bipolar disorder, lithium response, microRNA, common variants, genome-wide association study
INTRODUCTION
Bipolar disorder (BD) is a severe neuropsychiatric condition
categorized by recurrent episodes of depression and mania. BD
is common, with a lifetime prevalence of around 1% in the
general population (1). The elevated morbidity andmortality, the
typically early age at onset in young adulthood and the chronic
course of BD make it a major public health problem, and BD
is classified as one of the top 25 leading causes of the global
burden of disease (2). Epidemiological and molecular genetic
data strongly suggest that BD is a complex disorder (3) which
means that both genetic and environmental factors influence
illness risk. Based on twin studies the overall heritability of BD
has been estimated to be over 70% (4, 5), suggesting a substantial
involvement of genetic factors in the development of the disease.
Mood stabilizers are used as the first-line mode of medication
in the treatment of BD (6). Amongst these drugs, lithium is
used as a preventive agent for manic and depressive episodes (7),
suicide attempts, and death by suicide, and shows the greatest
support for long-term relapse prevention (8, 9). Consequently,
lithium is endorsed as a first-line and best-established long-term
treatment for BD, even though individual response is highly
variable (6, 8, 10). Evidence suggests that some of the variability
in lithium response has a genetic basis (11, 12). This hypothesis is
supported by the largest genome-wide association study (GWAS)
of lithium response to date, which was conducted by the
International Consortium on Lithium Genetics (ConLiGen) (13,
14). The study investigated genomic data of 2,563 BD patients,
identifying a genome-wide significant locus on chromosome 21,
which contains two long, non-coding RNA genes (lncRNAs) (14).
Non-coding RNAs (ncRNAs) are transcribed from DNA but
do not encode protein, and are involved in complex mechanisms
of gene regulation, particularly in fine regulation of the timing
and level of expression of their target genes. Another class
of ncRNAs whose role in the pathophysiology of psychiatric
disorders is emerging, is that of microRNAs (miRNAs). miRNAs
are short RNA molecules, which in the mature processed
form are 21 to 25-nucleotides in length, that work as post-
transcriptional regulators of gene expression (15). To create
a mature miRNA, a primary miRNA (pri-miRNA, typically
>1,000 nucleotides in length) is first transcribed, and forms
a secondary structure through self-base pairing (16, 17). This
is cleaved by the Drosha-DiGeorge syndrome critical region
gene 8 (Drosha-DGCR8) complex to create a pre-miRNA of
around 70 nucleotides (16). This double stranded RNA is
exported from the nucleus, cleaved by Dicer-transactivation-
responsive RNA-binding protein (Dicer-TRBP) to form the
mature miRNA (16), which can then target complementary
messenger RNA (mRNA) transcripts through the RNA-induced
silencing complex (RISC) to regulate expression (e.g., via mRNA
degradation or translational repression) (18). Several studies
have reported that miRNAs are potential predictors of treatment
response in complex genetic disorders (19–21) including lithium
response in BD (22). Furthermore, miRNAs are implicated
in biological pathways that regulate brain development and
synaptic plasticity (23, 24). Indeed, miR-137 has emerged as a
key risk gene in schizophrenia, and is known to regulate the
expression of several genes that are independently associated with
schizophrenia (25, 26). This implies the potential involvement of
miRNAs in the pathogenesis of psychiatric disorders including
BD. This hypothesis is further supported by the results of a
large GWAS of BD (27) where a single-nucleotide polymorphism
(SNP) flankingmiR-2113 was amongst the strongest findings.
Our group performed the first genome-wide analysis of
the involvement of miRNAs in the development of BD, in a
sample of 9,747 patients and 14,278 controls (28) in which we
identified nine BD-associated miRNAs that withstood stringent
Bonferroni-correction for multiple testing. However, it is largely
unknown whether these miRNAs are also associated with lithium
response in BD.
Therefore, the aim of the present study was to determine
whether common variants at any of the nine BD-associated
miRNAs contribute to the variance in lithium response in BD.
Furthermore, we systematically analyzed whether any other
miRNA is implicated in the response to lithium. For this purpose,
we performed window-based association testing for all known
miRNA coding genes in the largest GWAS dataset of lithium
response so far.
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MATERIALS AND METHODS
Sample Description
Analyses were performed using summary statistics from the
previously published GWAS of lithium response in BD patients
(n = 2,563 patients) (14). These GWAS datasets were collected
by ConLiGen and combine imputed genotype data from 22
contributing sites from four continents (Europe, America, Asia,
and Australia). The study was approved by the respective local
ethics committees. Written informed consent was obtained from
all participants prior to inclusion. The Alda scale was used to
create a dichotomous (good vs. poor response to lithium) and a
continuous measure (range 0–10) for the evaluation of long-term
treatment response to lithium. Briefly, the Alda scale measures
symptom improvement in the course of lithium treatment (A
score, range 0–10), which is then weighted against five criteria
(B score) that assess confounding factors, each scored 0, 1, or
2. The total score is calculated by subtracting the total B score
from the A score. Negative scores are set to 0 by default leading
to a total score range from 0 to 10. For the purpose of the
present analysis, subjects with a total score of 7 or higher were
defined as showing “good response” to lithium treatment in the
dichotomous phenotype. As continuous measurement, we used
the A score, but excluded all individuals with a total B score
greater than 4, as continuous measure (14, 29).
Definition of Candidate and Genome-Wide
miRNAs
Information on the nine BD-associated miRNAs was obtained
from our previously published genome-wide analysis of miRNAs
in BD (28). The chromosomal positions of the miRNAs were
obtained from the miRBase database (release 21) (30).
For the genome-wide miRNA association analysis
chromosomal positions for all 1,871 remaining miRNAs
were obtained from miRBase (release 21). miRNAs which were
not located on autosomal chromosomes (n= 120) were removed
from further analysis. Only miRNA genes which were covered
in the summary statistics of lithium response were included,
resulting in 1,692miRNAs which were tested in the genome-wide
analysis. For each gene, the entire preprocessed transcript ±
20 kilobase (kb) flanking sequence were analyzed, which would
include the majority of the regulatory regions (17).
miRNA-Based Association Tests
For the gene-based tests, we applied a set-based testing approach
adapted from the versatile gene-based test for GWAS (VEGAS2)
(31, 32) with a minor correction for the top-0.1-test option (33).
This algorithm is obtainable upon request. The top-0.1-test was
used since it showed the highest sensitivity with less than 1% false
positives across a variety of investigated gene-level methods (34).
The applied statistical algorithm is described in more detail in
the article by Mishra and Macgregor (32). Briefly, we grouped
SNPs within the miRNA loci ± 20 kb flanking sequence together
and calculated a set-based test statistic as the sum of the χ2 one
degree of freedom association P-values within the miRNA. The
observed test statistic was compared with simulated test statistics
from the multivariate normal distribution with correlation equal
to the corresponding LD structure as derived from the 1,000
Genomes phase 3 European population genotypes (35, 36). We
calculated an empirical miRNA-based P-value as the proportion
of simulated test statistics above the observed test statistic. For
the purposes of the present study, we used the top-0.1-test
option which summarizes the 10%most significant SNPs for each
miRNA.
Using the two summary statistics, miRNA-based P-values
were calculated for all miRNAs. The calculated miRNA-based
P-values were corrected for multiple testing according to
Benjamini-Hochberg.
Enrichment Tests
To test whether nominally significant SNPs were enriched within
miRNAs and their flanking regions, we conducted the Fisher’s
Exact Test for each summary statistic separately. Additionally, we
tested whether the number of cis-miR-eQTL SNPs identified by
Huan et al. (37) with a p-value of< 0.05 was higher than expected
using the Fisher’s Exact Test.
RESULTS
Of the nine tested BD-associated miRNAs, miR-499a showed
nominally significant P-values in both datasets (dichotomous
and continuous treatment response, Table 1). Of the remaining
1,692 miRNAs tested for the genome-wide miRNA analysis,
71 miRNAs showed nominally significant associations with
the dichotomous and 106 with the continuous treatment
response. Fifteen miRNAs revealed nominal significance with
both phenotypes. miR-633 showed the strongest association
with the continuous phenotype (p = 9.80E-04). Regarding
the dichotomous phenotype, miR-607 showed the strongest
association (p = 5.79E-04). No association between miRNAs
and treatment response to lithium in BD in either of the tested
conditions withstood multiple testing correction (Tables 1, 2).
The number of nominally significant SNPs in both of
our GWAS of lithium response located at miRNA loci
(n = 6,321 and n = 5,742 for continuous and dichotomous
measurement, respectively) was not significantly higher than
expected (p = 9.96E-01 and p = 1 for continuous and
dichotomous measurement, respectively, Fisher’s Exact Test).
The number of cis-miR-eQTL SNPs [identified by Huan et
al. (37)] in our summary statistics (n = 341 and n = 318 for
continuous and dichotomous measurement, respectively) were
significantly higher than expected (p = 3.31E-05 and p = 6.23E-
03 for continuous and dichotomous measurement, respectively,
Fisher’s Exact Test).
DISCUSSION
The current study investigated whether common variants at BD-
associated miRNA, or any other miRNA loci, contribute to the
differences in lithium response in BD patients.
miR-499a showed a nominally significant association with
lithium response in the candidate approach. Although the
association did not withstand correction for multiple testing, this
result provides some evidence that miR-499a might be involved
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TABLE 1 | Results of the window-based tests for the nine BD-associated miRNAs.
miRNA [position] n SNPs p miRNA pcorr miRNA Top SNP
[position]
p Top SNP
A) Dichotomous Treatment Response Measure
miR-499a [chr20:34990376-34990497] 87 1.71E-02 9.31E-01 rs117616040
[chr20:34977725]
2.27E-03
miR-135a-1 [chr3:52294219-52294308] 41 9.29E-02 9.31E-01 rs699465
[chr3:52276426]
1.98E-02
let-7g [chr3:52268278-52268361] 44 1.04E-01 9.31E-01 rs699465
[chr3:52276426]
1.98E-02
miR-644a [chr20:34466325-34466418] 35 2.03E-01 9.37E-01 rs7266300
[chr20:34449603]
9.76E-03
miR-708 [chr11:79402022-79402109] 130 3.51E-01 9.50E-01 rs12275848
[chr11:79416285]
7.89E-02
miR-1908 [chr11:61815161-61815240] 39 4.33E-01 9.50E-01 rs61897792
[chr11:61819414]
3.46E-02
miR-640 [chr19:19435063-19435158] 44 6.08E-01 9.55E-01 rs79954596
[chr19:19437834]
1.74E-01
miR-611 [chr11:61792495-61792561] 33 6.36E-01 9.55E-01 rs17762402
[chr11:61785729]
4.94E-02
miR-581 [chr5:53951504-53951599] 55 6.41E-01 9.55E-01 rs72644081
[chr5:53949850]
5.45E-02
B) Continuous Treatment Response Measure
miR-499a [chr20:34990376-34990497] 87 3.18E-02 7.52E-01 rs117616040
[chr20:34977725]
3.73E-03
miR-708 [chr11:79402022-79402109] 130 7.37E-02 8.02E-01 rs1355423
[chr11:79420556]
2.05E-02
miR-611 [chr11:61792495-61792561] 33 9.79E-02 8.22E-01 rs174532
[chr11:61781402]
3.30E-03
miR-644a [chr20:34466325-34466418] 35 1.95E-01 8.50E-01 rs7266300
[chr20:34449603]
6.47E-02
miR-1908 [chr11:61815161-61815240] 39 2.45E-01 8.64E-01 rs968567
[chr11:61828092]
3.20E-02
miR-640 [chr19:19435063-19435158] 45 2.69E-01 9.52E-01 rs79954596
[chr19:19437834]
1.15E-02
let-7g [chr3:52268278-52268361] 44 6.40E-01 9.81E-01 rs58315325
[chr3:52261812]
2.80E-02
miR-135a-1 [chr3:52294219-52294308] 41 7.81E-01 9.86E-01 rs34135146
[chr3:52279416]
6.28E-02
miR-581 [chr5:53951504-53951599] 55 9.22E-01 7.52E-01 rs697112
[chr5:53964849]
1.61E-01
microRNAs (miRNAs) are sorted according to their miRNA-based P-value. Genome build used is GRCh38 (hg38). Abbreviations: miRNA, microRNA; position, genomic position; nSNPs,
number of investigated SNPs; p miRNA, miRNA-based P-value; pcorr miRNA, Benjamini-Hochberg corrected miRNA-based P-value; Top SNP, top single-nucleotide polymorphism
within gene; p Top SNP, P-value of the Top SNP within gene.
in both development and treatment of BD. A previous study has
shown an upregulation of this miRNA in the prefrontal cortex
of patients with depression (38). In another study,miR-499a was
differentially expressed in the postmortem brains of BD patients
compared with controls (39). Furthermore, a recent study by
Banach et al. (40) reported lower expression levels of miR-499 in
the peripheral blood of BD patients during depressive episodes in
comparison to remission, suggesting miR-499 as a potential new
biomarker of illness state in BD.
Overall, the results of our candidate approach do not suggest
that individual BD-associated miRNAs might have a strong
influence on differential responses to lithium treatment in BD as
no association withstood multiple testing correction. On the one
hand, this might at least in part reflect that the power to detect
associations between common variants and lithium response
was limited in the present study, even though the ConLiGen
GWAS comprised several thousand individuals (41). On the
other hand, it might also indicate that the genetic factors that
contribute to BD etiology are different from those contributing to
treatment response or illness course. That there are such effects
in multifactorial diseases is supported by a study in ulcerative
colitis in which no SNPs from 163 inflammatory bowel disease
susceptibility loci (42) were found to be associated with the
disease course (43).
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TABLE 2 | Results of the window-based tests for the top five genome-wide miRNAs.
miRNA [position] n SNPs p miRNA pcorr miRNA Top SNP
[position]
p Top SNP
A) Dichotomous Treatment Response Measure
miR-607 [chr10:96828669-96828764] 48 5.79E-04 9.31E-01 rs111682442
[chr10:96823685]
2.73E-04
miR-8085 [chr19:44758657-44758721] 44 2.54E-03 9.31E-01 rs7249244
[chr19:44742441]
1.11E-04
miR-1296 [chr10:63372957-63373048] 62 4.13E-03 9.31E-01 rs10995527
[chr10:63387659]
5.47E-03
miR-4535 [chr22:48780295-48780353] 160 4.62E-03 9.31E-01 rs131016
[chr22:48775746]
1.24E-03
miR-451b [chr17:28861371-28861438] 44 5.11E-03 9.31E-01 rs34901720
[chr17:28852500]
2.17E-03
B) Continuous Treatment Response Measure
miR-633 [chr17:62944215-62944312] 29 9.80E-04 7.52E-01 rs1588368
[chr17:62938848]
1.21E-04
miR-6516 [chr17:77089417-77089497] 183 1.97E-03 8.02E-01 rs2411054
[chr17:77074245]
2.68E-05
miR-218-1 [chr4:20528275-20528384] 105 2.13E-03 8.22E-01 rs540146
[chr4:20544433]
6.08E-04
miR-7704 [chr2:176188843-176188901] 68 2.20E-03 8.50E-01 rs7589870
[chr2:176208720]
1.26E-03
miR-548e [chr10:110988926-110989013] 54 2.48E-03 8.64E-01 rs1327551
[chr10:111008438]
1.09E-03
microRNAs (miRNAs) are sorted according to their miRNA-based P-value. Genome build used is GRCh38 (hg38). Abbreviations: miRNA, microRNA; position, genomic position; nSNPs,
number of investigated SNPs; p miRNA, miRNA-based P-value; pcorr miRNA, Benjamini-Hochberg corrected miRNA-based P-value; Top SNP, top single-nucleotide polymorphism
within gene; p Top SNP, P-value of the Top SNP within gene.
In our systematic, genome-wide analysis of miRNAs, 106
miRNAs revealed nominally significant associations with the
continuous and 71 with the dichotomous lithium treatment
response.
The intergenic miR-633 located on chromosome 17 showed
the strongest association with the continuous phenotype
(p = 9.80E-04). To date, few published studies have investigated
the function of miR-633. Interestingly, one study reported that
miR-633 was differentially regulated in the cerebrospinal fluid
of patients with multiple sclerosis compared to patients with
other neurologic diseases. In addition, miR-633 differentiated
relapsing-remitting from secondary progressive multiple
sclerosis courses suggesting this miRNA as a potential biomarker
for disease course in multiple sclerosis (44).
miR-607, an intergenic miRNA located upstream of the
ligand dependent nuclear receptor corepressor (LCOR) gene on
chromosome 10, displayed the strongest association with the
dichotomous treatment response measure (p = 5.79E-04). The
function of this miRNA has been poorly characterized so far,
so that we cannot currently speculate about possible disease-
and treatment-relevant biological processes. Further research is
needed to elucidate the potential role of miR-607 in health or
disease.
No association between miRNAs and BD treatment response
to lithium in either of the tested conditions withstood multiple
testing correction. In addition, we did not observe a significant
enrichment for SNPs at all microRNA loci in the present study.
Given the limited power of our study, future investigation of
miRNAs in larger GWAS samples of BD and lithium response is
warranted as better understanding of genetic factors contributing
to disease etiology and treatment response might enable the
individualization of treatment as well as the identification of
novel therapeutic targets (45).
In the present study, we investigated all currently known
miRNAs regardless of their tissue or developmental expression
patterns. Approximately 70% of ncRNAs are thought to be
brain expressed (23) and are dynamically regulated during
development and over the lifespan. While the exact mechanisms
by which lithium exerts its therapeutic effects remain unclear,
pharmacokinetics and pharmacodynamics highlight the
importance of specific tissues (e.g., brain and kidney) in
treatment responsiveness (46, 47). Therefore, an analysis
including miRNAs expressed specifically in these tissues would
seem to be a rational follow-up step to reduce the multiple testing
burden and to narrow-down the miRNAs to those that a priori
may have a greater chance to be involved in lithium response.
Unfortunately, a systematic enrichment analyses for miRNAs in
particular tissues would be premature, since there are currently
no comprehensive expression databases derived from normal
tissue covering all known miRNAs investigated in the present
study. Data on miRNA expression at various developmental
stages is also still limited, as non-polyadenylated transcripts are
typically not captured with standard library preparation for RNA
sequencing. Furthermore, some miRNAs may only be expressed
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during early developmental stages but can still have an influence
on lithium response later on in life, particularly if expression
is induced by pharmaceutical treatment. Nevertheless, these
aspects remain important and should be considered in future
analyses as soon as more comprehensive data on miRNA
expression become available.
Using the present approach, we were not able to investigate
SNPs with trans-expression quantitative trait loci (eQTL)
effects on miRNAs. Previous studies suggest that a substantial
proportion of the identified miR-eQTLs are trans-eQTLs (48).
Therefore, future investigations into the molecular interactions
underlying the association between miRNA trans-eQTLs and
treatment response to lithium in BD are also warranted. Huan et
al. (37) conducted a genome-wide miR-eQTLmapping study and
found consistent evidence for 5,269 cis-miR-eQTLs for 76mature
microRNAs. The significant enrichment for cis-miR-eQTL SNPs
found in our summary statistics provides some evidence for the
importance of cis-miR-eQTLs in lithium response, although we
were not able to identify cis-miR-eQTL SNPs in our top findings
since those miRNAs were not among the 76 mature microRNAs
reported by Huan et al. (37).
Moreover, miRNAs only represent one class of non-coding
RNAs. In the ConLiGen GWAS a genome-wide significant locus
containing two lncRNAs was identified (14). Further analyses on
the contribution of lncRNAs to lithium response are therefore
warranted. This was beyond the scope of the present analysis as
the current understanding of the predicted structure of lncRNA
molecules and their biological functions remains limited (49).
In conclusion, our analyses do not provide strong evidence
that miRNAs are involved in individual response to lithium
treatment in BD, as no association between miRNAs and
lithium response withstood multiple testing correction. Our data
should still be interesting for follow-up of independent studies,
particularly when sufficient data is available to accurately define
the tissue and temporal expression profile of all human miRNAs,
which would allow a more targeted analysis of brain-expressed
miRNAs, thereby reducing the search space to miRNAs with
relevant expression profiles. We did not find any strong effect
that could be useful in terms of a personalized treatment for
individual patients. This does not exclude a possible (small) effect
of miRNAs on lithium response, and further independent and
even larger studies should be envisaged to clarify this question.
In parallel, the investigation of other biological mechanisms
possibly contributing to lithium treatment response may provide
insights for individualizing future pharmacotherapy in BD.
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